Screening for HIV-related neurocognitive impairment in clinical practice: challenges and opportunities (Q38122719)

29 August 2017

Screening for HIV-related neurocognitive impairment in clinical practice: challenges and opportunities (English)

1 reference

29 August 2017

T J Barber

1

1 reference

29 August 2017

D Bradshaw

2

1 reference

29 August 2017

D Hughes

3

1 reference

29 August 2017

L Leonidou

4

1 reference

29 August 2017

A Margetts

5

1 reference

29 August 2017

D Ratcliffe

6

1 reference

29 August 2017

S Thornton

7

1 reference

29 August 2017

A Pozniak

8

1 reference

29 August 2017

D Asboe

9

1 reference

29 August 2017

S Mandalia

10

1 reference

29 August 2017

M Boffito

11

1 reference

29 August 2017

N Davies

12

1 reference

29 August 2017

B Gazzard

13

1 reference

29 August 2017

J Catalan

14

1 reference

29 August 2017

22 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

26

1 reference

29 August 2017

160-168

1 reference

29 August 2017

2

1 reference

Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature

29 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Updated research nosology for HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Practice effects on the WAIS-III across 3- and 6-month intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Concurrent validity of a computer-based cognitive screening tool for use in adults with HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Practice effects and the use of alternate forms in serial neuropsychological testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Cognitive disorders in HIV-infected patients: are they HIV-related?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Neurocognitive impact of substance use in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

A screening algorithm for HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Clinical validation of the NeuroScreen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Utility of the HIV Dementia Scale (HDS) in identifying HIV dementia in a South African sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

The neuropathogenesis of AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

The impact of HIV-associated neuropsychological impairment on everyday functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

The importance of cognitive self-report in early HIV-1 infection: validation of a cognitive functional status subscale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment(*).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Validity of the Brief Patient Health Questionnaire Mood Scale (PHQ-9) in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Neurocognitive dysfunction in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Protease inhibitor monotherapy and the CNS: peace of mind?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

The AIDS dementia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

The Everyday Memory Questionnaire-revised: development of a 13-item scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Medication and finance management among HIV-infected adults: the impact of age and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Screening for cognitive impairment in human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

Cognitive dysfunction in HIV patients despite long-standing suppression of viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540121.2013.819401

10.1080/09540121.2013.819401

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference